201 related articles for article (PubMed ID: 35218445)
21. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma.
Herting F; Friess T; Bader S; Muth G; Hölzlwimmer G; Rieder N; Umana P; Klein C
Leuk Lymphoma; 2014 Sep; 55(9):2151-5160. PubMed ID: 24304419
[TBL] [Abstract][Full Text] [Related]
22. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
23. Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL.
Chu Y; Awasthi A; Lee S; Edani D; Yin C; Hochberg J; Shah T; Chung TH; Ayello J; van de Ven C; Klein C; Lee D; Cairo MS
Oncotarget; 2020 Aug; 11(32):3035-3047. PubMed ID: 32850008
[TBL] [Abstract][Full Text] [Related]
24. The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
Palazzo A; Herter S; Grosmaire L; Jones R; Frey CR; Limani F; Bacac M; Umana P; Oldham RJ; Marshall MJE; Cox KL; Turaj AH; Cragg MS; Klein C; Carter MJ; Tannheimer S
J Immunol; 2018 Apr; 200(7):2304-2312. PubMed ID: 29453281
[TBL] [Abstract][Full Text] [Related]
25. Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.
Franceschini E; Pellegrino M; Todisco V; Dolci G; Bettelli F; Meschiari M; Bedini A; Fregni-Serpini G; Grottola A; Guaraldi G; Pecorari M; Sarti M; Luppi M; Perno CF; Mussini C
Infection; 2023 Oct; 51(5):1577-1581. PubMed ID: 37076752
[TBL] [Abstract][Full Text] [Related]
26. CD20/TNFR1 dual-targeting antibody enhances lysosome rupture-mediated cell death in B cell lymphoma.
Kim JR; Lee D; Kim Y; Kim JY
Cancer Immunol Immunother; 2023 Jun; 72(6):1567-1580. PubMed ID: 36534148
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma.
Niitsu N; Hayama M; Okamoto M; Khori M; Higashihara M; Tamaru J; Hirano M
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4077-82. PubMed ID: 15217942
[TBL] [Abstract][Full Text] [Related]
28. Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.
Jamois C; Gibiansky E; Gibiansky L; Buchheit V; Sahin D; Cartron G; Marcus R; Hiddemann W; Seymour JF; Strefford JC; Hargreaves CE; Meneses-Lorente G; Frey N; Fingerle-Rowson G
Br J Clin Pharmacol; 2019 Jul; 85(7):1495-1506. PubMed ID: 30866056
[TBL] [Abstract][Full Text] [Related]
29. Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma.
Ueda Y; Asakura S; Wada S; Saito T; Yano T
Intern Med; 2022 Aug; 61(16):2523-2526. PubMed ID: 35650124
[TBL] [Abstract][Full Text] [Related]
30. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
van Meerten T; van Rijn RS; Hol S; Hagenbeek A; Ebeling SB
Clin Cancer Res; 2006 Jul; 12(13):4027-35. PubMed ID: 16818702
[TBL] [Abstract][Full Text] [Related]
31. Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Rafia R; Pandor A; Davis S; Stevens JW; Harnan S; Clowes M; Sorour Y; Cutting R
Pharmacoeconomics; 2018 Oct; 36(10):1143-1151. PubMed ID: 29594951
[TBL] [Abstract][Full Text] [Related]
32. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
Hiddemann W; Barbui AM; Canales MA; Cannell PK; Collins GP; Dürig J; Forstpointner R; Herold M; Hertzberg M; Klanova M; Radford J; Seymour JF; Tobinai K; Trotman J; Burciu A; Fingerle-Rowson G; Wolbers M; Nielsen T; Marcus RE
J Clin Oncol; 2018 Aug; 36(23):2395-2404. PubMed ID: 29856692
[TBL] [Abstract][Full Text] [Related]
33. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.
Cheney CM; Stephens DM; Mo X; Rafiq S; Butchar J; Flynn JM; Jones JA; Maddocks K; O'Reilly A; Ramachandran A; Tridandapani S; Muthusamy N; Byrd JC
MAbs; 2014; 6(3):749-55. PubMed ID: 24594909
[TBL] [Abstract][Full Text] [Related]
34. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
35. The clinical development of obinutuzumab for the treatment of follicular lymphoma.
Ma B; Ujjani C
Cancer Manag Res; 2017; 9():103-113. PubMed ID: 28435325
[TBL] [Abstract][Full Text] [Related]
36. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma.
Ma J; Zhao D; Zhen B; Xia Y; Gong Q; Chen W
J Comp Eff Res; 2023 Dec; 12(12):e230073. PubMed ID: 37916709
[TBL] [Abstract][Full Text] [Related]
38. A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.
Cheadle EJ; Lipowska-Bhalla G; Dovedi SJ; Fagnano E; Klein C; Honeychurch J; Illidge TM
Leukemia; 2017 Jul; 31(7):1611-1621. PubMed ID: 27890931
[TBL] [Abstract][Full Text] [Related]
39. Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review.
Davies A; Kater AP; Sharman JP; Stilgenbauer S; Vitolo U; Klein C; Parreira J; Salles G
Future Oncol; 2022 Aug; 18(26):2943-2966. PubMed ID: 35856239
[TBL] [Abstract][Full Text] [Related]
40. Fatal disseminated enterovirus infection in a patient with follicular lymphoma undergoing obinutuzumab maintenance therapy.
Heger JM; Eichenauer DA; Kasper P; Böll B; Shimabukuro-Vornhagen A; Kochanek M
Eur J Haematol; 2019 Sep; 103(3):268-271. PubMed ID: 31211882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
